Clinical trial
Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With…
NCT00153985 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00153985 |
|---|---|
| Title | Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies |
| Official title | Multi-Center Study Using Allogeneic Stem Cell Transplantation Following Reduced Intensity Chemotherapy in Patients With Hemoglobinopathies |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Beth Israel Deaconess Medical Center Massachusetts General Hospital Brigham and Women's Hospital Emory University Feist-Weiller Cancer Center at Louisiana State University Health Sciences Ohio State… |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hemoglobinopathies, Sickle Cell Disease, Thalassemia |
| Intervention type | Drug, Procedure |
| Interventions | Busulfex, Fludarabine, Alemtuzumab, Stem Cell Transfusion |
| Enrollment | 2 |
| Start date | Mar 1, 2004 |
| Primary completion | Mar 1, 2008 |
| Completion | Jul 1, 2009 |
| First posted | Sep 12, 2005 |
| Last update posted | Jul 30, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: